FDA grants NeuroRx drug NRX-101 breakthrough therapy certification
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, NeuroRx(http://announced that itsdrug(http://NRX-101 has been certified by the U.SFDA(http://NRX-101 is primarily used to treat patients with severe bipolar depression with acute suicidal thoughts and behaviour (ASIB), and is the first oral quick-acting antidepressant to be awarded a breakthrough therapy certificationNeuroRx published its encouraging findings in a recent report in the STABIL-B study, which showed that NRX-101 was well tolerated with no serious adverse events and disruptive side effectsNRX-101
NRX-101 is an oral drug combination consisting of a fixed dose of D-cyclic serine (DCS), NMDA antagonist, lurasidone, with 5-HT2a receptor antagonist activityDCS increases levels of two neurotransmitters, glutamate and glutamine (Glx), compared to all previously approved antidepressantstherefore, NRX-101 may represent a new class of antidepressants that has the potential to truly reduce suicidal thoughts in patients with severe bipolar disorderClinical data obtained from the Multicenter STABIL-B feasibility study to assess the clinical effects of NRX-101 compared to the lurasidone control groupNeuroRx is currently conducting a key 2b/3 clinicaltrial(http://at SPA to treat patients with severe bipolar depression and acute suicidal thoughtafters after the initial stabilization of ketamine by comparing daily oral NRX-101 therapy with standard treatment (lurasidone)previously, NeuroRx was awarded fast TRACK certification by the FDA in August 2017
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
